Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
Does the presence of bronchiectasis change your approach to a patient with otherwise well-controlled patient with RA?
Related Questions
Are there any recommendations for restarting JAKi after a provoked DVT?
Do you avoid the use of TNF inhibitors in patients with RA-ILD?
How would you manage a patient with hidradenitis suppurativa and inflammatory arthritis (RA vs. PsA)?
Would you consider using a JAK inhibitor for a patient with RA associated scleritis?
How do you help patients understand the difference between prolonged morning stiffness and pain?
Would you continue Jak inhibitor therapy in a patient with long standing, previously refractory RA in their 60s who was found to have stenosis of the left common femoral artery and no other history of arteriosclerotic disease?
For patients with obesity and elevated alk phos who have RA, do you check a fibroscan or serum NASH fibrosure test before starting methotrexate or leflunomide?
How do you approach treatment of a patient with active RA and a history of Lynch Syndrome?
How do you approach treatment selection in patients with rheumatoid arthritis and severe COPD?
What is your approach to monitoring patients referred for high titer +RF and +CCP but without active symptoms of inflammatory arthritis?
